ALAMEDA, Calif.--(BUSINESS WIRE)--Celera Corporation (NASDAQ:CRA) today announced that it has licensed its KIF6 discoveries to the University of California on behalf of its San Francisco Campus. Through this agreement, the University of California, San Francisco (UCSF) will be the first laboratory in the United States in addition to Berkeley HeartLab, a subsidiary of Celera Corporation, to have access to the relevant intellectual property to develop and perform an in-house test for the KIF6 gene variant previously reported by Celera and its collaborators. The KIF6 gene encodes a kinesin-like protein 6 (KIF6). Published research studies have shown an association between KIF6 and cardiovascular risk and statin benefit1-4.
